Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.
CAIN457H1301
Phase 3 small_molecule completed
Quick answer
Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection. for Ankylosing Spondylitis is a Phase 3 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Pharmaceuticals
- Indication
- Ankylosing Spondylitis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed